Microarray technology: A review of new strategies to discover candidate vulnerability genes in psychiatric disorders

William E. Bunney, Blynn G. Bunney, Marquis P. Vawter, Hiroaki Tomita, Jun Li, Simon J. Evans, Prabhakara V Choudary, Richard M. Myers, Edward G. Jones, Stanley J. Watson, Huda Akil

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Objective: An international effort is in progress to discover candidate genes and pathways associated with psychiatric disorders, including two of the most serious diseases, schizophrenia and mood disorders, through the use of new technology - microarrays. Instead of studying one gene at a time, microarrays provide the opportunity to analyze thousands of genes at once. Method: This article reviews the steps in this discovery process, including the acquisition and characterization of high-quality postmortem brain tissue, RNA extraction, and preparation and use of microarray technology. Two alternative microarray methods and factors affecting the quality of array data are reviewed. Results: New analytical strategies are being developed to process the massive data sets generated by microarray studies and to define the significance of implicated genes. Array results must be validated by other methods, including in situ hybridization and real-time polymerase chain reaction. Identified genes can also be evaluated in terms of their chromosomal locations and possible overlap with regions of suggestive linkage or association identified with genome-wide linkage analysis in psychiatry and in terms of overlap with genes identified by microarray studies in animals administered psychoactive drugs. Microarray studies are only the first major step in the process. Further efforts in the investigation involve multiple strategies for studying function and gene structure, including transgenic and knockout animal studies. Conclusions: Microarrays present a methodology that can identify genes or pathways for new and unique potential drug targets, determine premorbid diagnosis, predict drug responsiveness for individual patients, and, eventually, initiate gene therapy and prevention strategies.

Original languageEnglish (US)
Pages (from-to)657-666
Number of pages10
JournalAmerican Journal of Psychiatry
Volume160
Issue number4
DOIs
StatePublished - Apr 2003
Externally publishedYes

Fingerprint

Psychiatry
Technology
Genes
Genetically Modified Animals
Psychotropic Drugs
Mood Disorders
Pharmaceutical Preparations
Genetic Therapy
In Situ Hybridization
Real-Time Polymerase Chain Reaction
Schizophrenia
Genome
RNA
Brain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Microarray technology : A review of new strategies to discover candidate vulnerability genes in psychiatric disorders. / Bunney, William E.; Bunney, Blynn G.; Vawter, Marquis P.; Tomita, Hiroaki; Li, Jun; Evans, Simon J.; Choudary, Prabhakara V; Myers, Richard M.; Jones, Edward G.; Watson, Stanley J.; Akil, Huda.

In: American Journal of Psychiatry, Vol. 160, No. 4, 04.2003, p. 657-666.

Research output: Contribution to journalArticle

Bunney, WE, Bunney, BG, Vawter, MP, Tomita, H, Li, J, Evans, SJ, Choudary, PV, Myers, RM, Jones, EG, Watson, SJ & Akil, H 2003, 'Microarray technology: A review of new strategies to discover candidate vulnerability genes in psychiatric disorders', American Journal of Psychiatry, vol. 160, no. 4, pp. 657-666. https://doi.org/10.1176/appi.ajp.160.4.657
Bunney, William E. ; Bunney, Blynn G. ; Vawter, Marquis P. ; Tomita, Hiroaki ; Li, Jun ; Evans, Simon J. ; Choudary, Prabhakara V ; Myers, Richard M. ; Jones, Edward G. ; Watson, Stanley J. ; Akil, Huda. / Microarray technology : A review of new strategies to discover candidate vulnerability genes in psychiatric disorders. In: American Journal of Psychiatry. 2003 ; Vol. 160, No. 4. pp. 657-666.
@article{c74892026e134ab0b5db2387c641fc3a,
title = "Microarray technology: A review of new strategies to discover candidate vulnerability genes in psychiatric disorders",
abstract = "Objective: An international effort is in progress to discover candidate genes and pathways associated with psychiatric disorders, including two of the most serious diseases, schizophrenia and mood disorders, through the use of new technology - microarrays. Instead of studying one gene at a time, microarrays provide the opportunity to analyze thousands of genes at once. Method: This article reviews the steps in this discovery process, including the acquisition and characterization of high-quality postmortem brain tissue, RNA extraction, and preparation and use of microarray technology. Two alternative microarray methods and factors affecting the quality of array data are reviewed. Results: New analytical strategies are being developed to process the massive data sets generated by microarray studies and to define the significance of implicated genes. Array results must be validated by other methods, including in situ hybridization and real-time polymerase chain reaction. Identified genes can also be evaluated in terms of their chromosomal locations and possible overlap with regions of suggestive linkage or association identified with genome-wide linkage analysis in psychiatry and in terms of overlap with genes identified by microarray studies in animals administered psychoactive drugs. Microarray studies are only the first major step in the process. Further efforts in the investigation involve multiple strategies for studying function and gene structure, including transgenic and knockout animal studies. Conclusions: Microarrays present a methodology that can identify genes or pathways for new and unique potential drug targets, determine premorbid diagnosis, predict drug responsiveness for individual patients, and, eventually, initiate gene therapy and prevention strategies.",
author = "Bunney, {William E.} and Bunney, {Blynn G.} and Vawter, {Marquis P.} and Hiroaki Tomita and Jun Li and Evans, {Simon J.} and Choudary, {Prabhakara V} and Myers, {Richard M.} and Jones, {Edward G.} and Watson, {Stanley J.} and Huda Akil",
year = "2003",
month = "4",
doi = "10.1176/appi.ajp.160.4.657",
language = "English (US)",
volume = "160",
pages = "657--666",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "4",

}

TY - JOUR

T1 - Microarray technology

T2 - A review of new strategies to discover candidate vulnerability genes in psychiatric disorders

AU - Bunney, William E.

AU - Bunney, Blynn G.

AU - Vawter, Marquis P.

AU - Tomita, Hiroaki

AU - Li, Jun

AU - Evans, Simon J.

AU - Choudary, Prabhakara V

AU - Myers, Richard M.

AU - Jones, Edward G.

AU - Watson, Stanley J.

AU - Akil, Huda

PY - 2003/4

Y1 - 2003/4

N2 - Objective: An international effort is in progress to discover candidate genes and pathways associated with psychiatric disorders, including two of the most serious diseases, schizophrenia and mood disorders, through the use of new technology - microarrays. Instead of studying one gene at a time, microarrays provide the opportunity to analyze thousands of genes at once. Method: This article reviews the steps in this discovery process, including the acquisition and characterization of high-quality postmortem brain tissue, RNA extraction, and preparation and use of microarray technology. Two alternative microarray methods and factors affecting the quality of array data are reviewed. Results: New analytical strategies are being developed to process the massive data sets generated by microarray studies and to define the significance of implicated genes. Array results must be validated by other methods, including in situ hybridization and real-time polymerase chain reaction. Identified genes can also be evaluated in terms of their chromosomal locations and possible overlap with regions of suggestive linkage or association identified with genome-wide linkage analysis in psychiatry and in terms of overlap with genes identified by microarray studies in animals administered psychoactive drugs. Microarray studies are only the first major step in the process. Further efforts in the investigation involve multiple strategies for studying function and gene structure, including transgenic and knockout animal studies. Conclusions: Microarrays present a methodology that can identify genes or pathways for new and unique potential drug targets, determine premorbid diagnosis, predict drug responsiveness for individual patients, and, eventually, initiate gene therapy and prevention strategies.

AB - Objective: An international effort is in progress to discover candidate genes and pathways associated with psychiatric disorders, including two of the most serious diseases, schizophrenia and mood disorders, through the use of new technology - microarrays. Instead of studying one gene at a time, microarrays provide the opportunity to analyze thousands of genes at once. Method: This article reviews the steps in this discovery process, including the acquisition and characterization of high-quality postmortem brain tissue, RNA extraction, and preparation and use of microarray technology. Two alternative microarray methods and factors affecting the quality of array data are reviewed. Results: New analytical strategies are being developed to process the massive data sets generated by microarray studies and to define the significance of implicated genes. Array results must be validated by other methods, including in situ hybridization and real-time polymerase chain reaction. Identified genes can also be evaluated in terms of their chromosomal locations and possible overlap with regions of suggestive linkage or association identified with genome-wide linkage analysis in psychiatry and in terms of overlap with genes identified by microarray studies in animals administered psychoactive drugs. Microarray studies are only the first major step in the process. Further efforts in the investigation involve multiple strategies for studying function and gene structure, including transgenic and knockout animal studies. Conclusions: Microarrays present a methodology that can identify genes or pathways for new and unique potential drug targets, determine premorbid diagnosis, predict drug responsiveness for individual patients, and, eventually, initiate gene therapy and prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=0038811923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038811923&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.160.4.657

DO - 10.1176/appi.ajp.160.4.657

M3 - Article

C2 - 12668351

AN - SCOPUS:0038811923

VL - 160

SP - 657

EP - 666

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 4

ER -